A study investigating the molecular mechanisms underlying disease progression along the NAFLD spectrum revealed elevated hepatic expression levels of NKG2D ligands and IL-17A in the early stages of NASH development. This evidence concerns the gene IL17A and metabolic dysfunction-associated steatotic liver disease.